<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05005897</url>
  </required_header>
  <id_info>
    <org_study_id>9305-150426</org_study_id>
    <secondary_id>U1111-1267-0112</secondary_id>
    <nct_id>NCT05005897</nct_id>
  </id_info>
  <brief_title>Early Infant Micronutrition and Development</brief_title>
  <acronym>RART</acronym>
  <official_title>Vitamin B12 Status in Infancy and the Effect of Providing Vitamin B12 to Infants With Signs of Suboptimal Vitamin B12 Status - a Registry-based, Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sykehuset Innlandet HF</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Bergen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Oslo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Inland Norway University of Applied Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sykehuset Innlandet HF</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Globally, vitamin B12 deficiency is one of the most common micronutrient deficiencies. Poor&#xD;
      status is also seen in affluent countries such as in Norway. Vitamin B12 is crucial for&#xD;
      normal cell division and differentiation and necessary for the development and myelination of&#xD;
      the central nervous system. Deficiency is also associated with impaired fetal and infant&#xD;
      growth. In the proposed study we will measure the effect of daily oral vitamin B12&#xD;
      supplementation infants on neurodevelopment. We also aim to measure the impact of B12&#xD;
      supplementation on several other outcomes.&#xD;
&#xD;
      Study design: Individually randomized double-blind placebo-controlled trial breastfed infants&#xD;
      who will be assigned to a screening group (in which measurements will be obtained&#xD;
      immediately) or a control group (in which serum will be stored and measurements done after&#xD;
      one year).&#xD;
&#xD;
      Pregnant women will be informed about the study during their first antenatal visit at the&#xD;
      clinic and that we will re-approach them on their 6-week visit to their public health nurse.&#xD;
      Infants who are deficient will be treated with peroral or intramuscular injections with 400&#xD;
      µg cyano-cobalamin.&#xD;
&#xD;
      Infants in the control group will not be offered any intervention their blood sample will be&#xD;
      stored for one year and then analyzed for the same nutrients as the intervention group.&#xD;
&#xD;
      Outcomes: Primary: (i) neurodevelopment in children measured at 12 months of age (ii) growth&#xD;
      in children measured by attained weight and length at 12 months. Secondary: (i)&#xD;
      neurodevelopment and cognitive functioning in children later in life&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 15, 2021</start_date>
  <completion_date type="Anticipated">October 15, 2029</completion_date>
  <primary_completion_date type="Anticipated">October 15, 2025</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Neurodevelopment</measure>
    <time_frame>12 months of age</time_frame>
    <description>Bayley Scales of Infant Development 4th edition</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Prevalence of vitamin B12 deficiency</measure>
    <time_frame>1-3 months of age</time_frame>
    <description>Number of children with elevated plasma homocysteine or low cobalamin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Prevalence of other vitamin deficiencies</measure>
    <time_frame>1-3 months of age</time_frame>
    <description>Number of infants with vitamin deficiencies other than vitamin B12 deficiency</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neurodevelopment measured by the Ages and Stages Questionaire</measure>
    <time_frame>4-12 months of age</time_frame>
    <description>Ages and Stages Questionnaire version 3 repeated throughout infancy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vagal tone</measure>
    <time_frame>12 months of age</time_frame>
    <description>Heart rate variability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eye tracking</measure>
    <time_frame>12 months of age</time_frame>
    <description>Visual acuity, visuospatial orientation, and attention to social cues</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurodevelopment later in childhood</measure>
    <time_frame>5 years</time_frame>
    <description>General cognitive abilities (&quot;IQ&quot;) assessed by the Wechsler Preschool and Primary Scale of Intelligence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>3 months after treatment with vitamin B12</time_frame>
    <description>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Thyroid function</measure>
    <time_frame>12 months of age</time_frame>
    <description>Infant thyroid function measured by the concentration of the hormones TSH, T3, and T4</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Vitamin B 12 Deficiency</condition>
  <arm_group>
    <arm_group_label>Screening - treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>From 6 weeks of age, infants will be screened for elevated plasma total homocysteine concentrations. Those who have a concentration above the defined cut-off will be treated with cobalamin (vitamin B12).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The control-group sample will be stored and analyzed when the child is 12 months old. Those with elevated tHcy will contribute to the control group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cyanocobalamin</intervention_name>
    <description>Intramuscular injection of 400 µg cobalamin to children with elevated thcy at enrollment</description>
    <arm_group_label>Screening - treatment</arm_group_label>
    <other_name>Vitamin B12</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Availability of informed verbal consent&#xD;
&#xD;
          2. Plan to reside in the defined study area for the next 12 months&#xD;
&#xD;
          3. Mothers intend to breastfeed their children for at least 8 months, and exclusively for&#xD;
             4 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Severe systemic illness requiring hospitalization&#xD;
&#xD;
          2. Growth retardation&#xD;
&#xD;
          3. Severe congenital malformations&#xD;
&#xD;
          4. Plasma cobalamin concentration &lt;148 pmol/L (These children will be treated for vitamin&#xD;
             B12 deficiency and not included in the RCT, but will be included in the cohort design)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>2 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tor A Strand, M.D. / Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sykehuset Innlandet HF</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carolien Konijnenberg, Ph.D</last_name>
    <phone>+47 61 28 74 94</phone>
    <email>carolien.konijnenberg@inn.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kjersti S Bakken, Ph.D.</last_name>
    <phone>+47 957 81 349</phone>
    <email>Kjersti.Sletten.Bakken@sykehuset-innlandet.no</email>
  </overall_contact_backup>
  <reference>
    <citation>Hay G, Johnston C, Whitelaw A, Trygg K, Refsum H. Folate and cobalamin status in relation to breastfeeding and weaning in healthy infants. Am J Clin Nutr. 2008 Jul;88(1):105-14.</citation>
    <PMID>18614730</PMID>
  </reference>
  <reference>
    <citation>Torsvik I, Ueland PM, Markestad T, Bjørke-Monsen AL. Cobalamin supplementation improves motor development and regurgitations in infants: results from a randomized intervention study. Am J Clin Nutr. 2013 Nov;98(5):1233-40. doi: 10.3945/ajcn.113.061549. Epub 2013 Sep 11.</citation>
    <PMID>24025626</PMID>
  </reference>
  <reference>
    <citation>Dror DK, Allen LH. Effect of vitamin B12 deficiency on neurodevelopment in infants: current knowledge and possible mechanisms. Nutr Rev. 2008 May;66(5):250-5. doi: 10.1111/j.1753-4887.2008.00031.x. Review.</citation>
    <PMID>18454811</PMID>
  </reference>
  <reference>
    <citation>Kvestad I, Taneja S, Kumar T, Hysing M, Refsum H, Yajnik CS, Bhandari N, Strand TA; Folate and Vitamin B12 Study Group. Vitamin B12 and Folic Acid Improve Gross Motor and Problem-Solving Skills in Young North Indian Children: A Randomized Placebo-Controlled Trial. PLoS One. 2015 Jun 22;10(6):e0129915. doi: 10.1371/journal.pone.0129915. eCollection 2015.</citation>
    <PMID>26098427</PMID>
  </reference>
  <reference>
    <citation>Bjørke-Monsen AL. Is exclusive breastfeeding ensuring an optimal micronutrient status and psychomotor development in infants? Clin Biochem. 2014 Jun;47(9):714. doi: 10.1016/j.clinbiochem.2014.05.022. Epub 2014 May 17.</citation>
    <PMID>24845709</PMID>
  </reference>
  <reference>
    <citation>Forssman L, Ashorn P, Ashorn U, Maleta K, Matchado A, Kortekangas E, Leppänen JM. Eye-tracking-based assessment of cognitive function in low-resource settings. Arch Dis Child. 2017 Apr;102(4):301-302. doi: 10.1136/archdischild-2016-310525. Epub 2016 Aug 22.</citation>
    <PMID>27551061</PMID>
  </reference>
  <reference>
    <citation>Graziano P, Derefinko K. Cardiac vagal control and children's adaptive functioning: a meta-analysis. Biol Psychol. 2013 Sep;94(1):22-37. doi: 10.1016/j.biopsycho.2013.04.011. Epub 2013 May 4.</citation>
    <PMID>23648264</PMID>
  </reference>
  <reference>
    <citation>Strand TA, Taneja S, Ueland PM, Refsum H, Bahl R, Schneede J, Sommerfelt H, Bhandari N. Cobalamin and folate status predicts mental development scores in North Indian children 12-18 mo of age. Am J Clin Nutr. 2013 Feb;97(2):310-7. doi: 10.3945/ajcn.111.032268. Epub 2013 Jan 2.</citation>
    <PMID>23283502</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 9, 2021</study_first_submitted>
  <study_first_submitted_qc>August 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 16, 2021</study_first_posted>
  <last_update_submitted>August 11, 2021</last_update_submitted>
  <last_update_submitted_qc>August 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nutrition</keyword>
  <keyword>Vitamins</keyword>
  <keyword>Breastfeeding</keyword>
  <keyword>Infant</keyword>
  <keyword>Neurodevelopment</keyword>
  <keyword>Growth</keyword>
  <keyword>Clinical trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin B 12 Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin B 12</mesh_term>
    <mesh_term>Hydroxocobalamin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>We plan to share data with other researchers.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>Data will be available not later than 5 years after the study have completed enrollment and the first year of follow-up of all children.</ipd_time_frame>
    <ipd_access_criteria>Data available on request. In order to meet ethical requirements for the use of confidential patient data, requests must be approved by Regional Committee for Medical and Health Research Ethics in Norway.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

